Bristol-Myers Squibb (BMY) Declares $0.40 Quarterly Dividend; 2.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability
March 5, 2018 9:19 AM ESTBofA/Merrill Lynch raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $68.00 (from $64.00) while maintaining a Buy rating, ahead of the company's CM-227 Opdivo+Yervoy data presentation.
Analyst Jason Gerberry notes a positive outlook on the shares, ahead of BMY's CM-227... More
